KCF-18 10 mg

A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation


The antagonist peptide KCF18 was designed to inhibit cytokine-induced inflammatory response by binding to the cytokines simultaneously. The anti-inflammatory effect of KCF18 is attributed to the reduction of proinflammatory cytokine–receptor interactions on endothelial cells and monocytes, thereby suppressing cytokine mRNA expression and monocyte binding and transmigration.







    ©2017 by CanLab. Proudly created with Wix.com